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Accepted 24 December 2014; Published online 7 February 2015AbstractObjectives: To map the current status of head-to-head comparative randomized evidence and to assess whether funding may impact on
trial design and results.
Study Design and Setting: From a 50% random sample of the randomized controlled trials (RCTs) published in journals indexed in
PubMed during 2011, we selected the trials with 100 participants, evaluating the efficacy and safety of drugs, biologics, and medical
devices through a head-to-head comparison.
Results: We analyzed 319 trials. Overall, 238,386 of the 289,718 randomized subjects (82.3%) were included in the 182 trials funded
by companies. Of the 182 industry-sponsored trials, only 23 had two industry sponsors and only three involved truly antagonistic compar-
isons. Industry-sponsored trials were larger, more commonly registered, used more frequently noninferiority/equivalence designs, had high-
er citation impact, and were more likely to have ‘‘favorable’’ results (superiority or noninferiority/equivalence for the experimental
treatment) than nonindustry-sponsored trials. Industry funding [odds ratio (OR) 2.8; 95% confidence interval (CI): 1.6, 4.7] and noninfer-
iority/equivalence designs (OR 3.2; 95% CI: 1.5, 6.6), but not sample size, were strongly associated with ‘‘favorable’’ findings. Fifty-five of
the 57 (96.5%) industry-funded noninferiority/equivalence trials got desirable ‘‘favorable’’ results.
Conclusion: The literature of head-to-head RCTs is dominated by the industry. Industry-sponsored comparative assessments system-
atically yield favorable results for the sponsors, even more so when noninferiority designs are involved.  2015 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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It is becoming increasingly common to have multiple
treatment options for managing many medical conditions.
Most randomized trials to date have evaluated the effective-
ness and safety of active interventions against inactiveM.E.F and L.M. equally contributed to this work.
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licenses/by-nc-nd/4.0/).controls (placebo, no treatment, or standard of care) [1].
However, comparative evidence from head-to-head random-
ized comparisons may be indispensable to capture the rela-
tive benefits and harms of alternative interventions [2e4].
Previous empirical assessments of trials on head-to-head
comparisons have focused mostly on single domains or spe-
cialties, such as cardiovascular medicine and psychiatry
[5e8]. These assessments have suggested that most of these
trials are sponsored by the industry. Head-to-head compar-
isons comprise a very small proportion of the industry-
sponsored clinical trials agenda, which is vastly dominated
by trials that involve testing only a single product by aess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
Most head-to-head comparative evidence is procured
by industry-sponsored trials. Head-to-head industry
trials tend to be larger, more frequently registered
and to yield ‘‘favorable’’ results for the experimental
treatment. They also use noninferiority/equivalence
designs more frequently than nonindustry-sponsored
trials. Industry funding and noninferiority/equiva-
lence designs are strong predictors of ‘‘favorable’’
findings, and when they coexist, almost all trials get
desirable ‘‘favorable’’ results.
What this study adds to what was known?
It has been speculated whether companies tend to
avoid head-to-head comparisons and to avoid jeop-
ardizing their market share by unfavorable results.
However, we found a strong dominance of the indus-
try in the influential agenda of head-to-head compar-
isons and a high prevalence of results that are
favorable for the sponsoring companies in this
literature.
What is the implication and what should change
now?
Given the pivotal importance of head-to-head trials in
generating influential comparative evidence, consid-
eration should be given to allowing the conduct of
more large trials of comparative effectiveness and
safety under the control of nonprofit entities.
single manufacturer sponsor [9]. However, given the pivotal
importance of head-to-head trials in generating influential
comparative evidence [2,3], it is important to understand
the profile of currently performed head-to-head randomized
comparisons and whether their sponsorship has any impact
on their design and their results. For randomized trials in
general, there are suggestions that industry funding may
be associated with more favorable results and conclusions
[10e18], but also better methodological quality compared
with nonindustry-funded trials [19]. It would be interesting
to assess whether the profile and characteristics, types of
designs used, and results of head-to-head comparisons in
randomized trials are also influenced by their sponsoring.
Head-to-head comparisons in particular pose some addi-
tional design challenges, such as the choice of superiority
or noninferiority/equivalence designs [20,21], which may
also affect the final inferences drawn. Moreover, given that
two or more active treatments are involved in the compar-
ison, in theory more than one sponsor may be involved and
antagonistic situations may ensue if the sponsors are man-
ufacturers of the compared interventions. Preliminary
812 M.E. Flacco et al. / Journal of Clievidence suggests that companies avoid to cosponsor the
same trial with such antagonistic comparisons [9]. This
avoidance may generate fragmented evidence, where little
evidence is available on interventions that have been man-
ufactured by different companies. It would be interesting to
examine whether this is a common pattern across a large
number of head-to-head comparisons.
To map the current status of head-to-head comparative
evidence, here we analyzed a large sample of recently pub-
lished head-to-head randomized clinical trials covering a
wide range of clinical conditions. We evaluated trials with
at least 100 participants because these larger trials are the
ones that are most likely to have a greater impact on our
perceptions of the accumulated evidence and therefore also
on medical practice. We specifically focused on the spon-
soring of these trials and whether sponsoring by the indus-
try affected the characteristics, design, and findings/
conclusions from these studies.2. Methods
2.1. Bibliographic search and inclusion study criteria
OnMarch 15, 2013, we performed a search in PubMed us-
ing the following terms: [Randomized controlled trial OR
randomised controlled trial OR randomized trial OR rando-
mised trial] and restricted the results to trials published in
any language in 2011. After the methodology by Resnik
et al. [22,23], we randomly selected 50% of the 20,088 items
published during 2011. Each itemwas assigned a number ac-
cording to the order of appearance in PubMed. A computer-
generated random sequence was then created (from 1 to
20,088 without replacement), and the first 50% items were
selected for review. We then screened all trials for inclusion
based on the abstract or, if needed, the full text.
We included only randomized controlled trials (RCTs)
evaluating the efficacy and safety of drugs, biologics, or
medical devices, in which two or more interventions were
directly compared, regardless of whether there were also
common backbone treatments (common treatments across
study arms). Trials comparing an intervention against pla-
cebo as well as comparing different doses or ways of
administration of the same intervention were excluded,
regardless of whether additional backbone treatments were
given to all study arms. Also, we limited our search to trials
with sample size 100 to avoid the inclusion of smaller
studies that may be less influential on evidence-based infer-
ences and their application to medical practice. The
threshold of n 5 100 is arbitrary and was set a priori.2.1.1. Data extraction
Eligible studies were scrutinized to extract the following
data: sample size; study location(s); disease or condition(s);
compared interventions; backbone interventions; registration
in at least one trial registry among ClinicalTrials.gov, WHO
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ical Trials Registries (if no trial registration number was pro-
vided in the article, we manually searched the previously
mentioned databases to identify the corresponding trial using
the following information: trial sample, interventions, primary
and secondary outcomes, and funding sources); design (supe-
riority, noninferiority, equivalence); ‘‘favorable’’ or ‘‘unfavor-
able’’ trial results for the experimental therapy: a trial was
classified as ‘‘favorable’’ if, for at least one main outcome
among those defined in the protocol, the experimental therapy
was significantly (P! 0.05) better than the standard therapy
(in superiority trials), the experimental therapy was not sub-
stantially worse than the standard therapy (in noninferiority
trials), or the effects of the treatments differed by nomore than
the equivalence margin (in equivalence trials) [24,25]; name
of the journal publishing the trial, its impact factor value ac-
cording to the JCR 2012, and number of citations received
by each trial in Scopus until March 15, 2013; type of funding
source (not reported, governmental and/or other nonprofit or-
ganizations, industry).A trialwas classified as industry funded
if: (1) an explicit acknowledgment of support from private in-
dustrywas provided in the article, or stated in the acknowledg-
ment section, or (if the trial was registered) declared in the
corresponding trial registration record; or (2) at least one
author was a company employee, or received grants from
the company, or held stocks or options; or (3) the statistical
analysis was performed by the company [19,26]. In case of
multiple sources of funding, a trial was considered industry
funded if the points (1) or (2) weremet, regardless of the pres-
ence of other, nonprofit sources of funding, or the affiliations
of the co-authors. We also noted the name(s) of the funding
source(s) (if no funding source was listed in the article, we
checked the corresponding trial registration record); owner(s)
of the products under evaluation (the ones compared and any
backbone intervention); authors’ affiliation (industry,
nonprofit, academic) and name of the affiliation company;
and presence (yes/no) of a conflict of interestwith the sponsors
or owners, as declared in the article.When not explicitly stated
in the article, the presence of a conflict of interest was deduced
if at least one of the authorswas an employee of the same com-
pany sponsoring the trial or commercializing one of the prod-
ucts compared or used as backbone intervention.
Because financial agreements among companies are
common, we tried to identify and merge with the mother
company any affiliates, subsidiaries, or branches (even with
different names), which were seemingly owning or spon-
soring different interventions. For each drug, we extracted
the ownership at the time of trial publication (2011). When
a drug was manufactured by more than one company, we
further tried to identify the owners of compared interven-
tions by checking article and/or trial registry entries
because most of them reported the trade names (and the
manufacturers) of compared interventions. If these data
were not available, we retrieved useful information on
drugs manufacturer and sponsors by perusing the 2011 Edi-
tion of the Physician’s Desk Reference (65th Edition, 2011)and/or the British National Formulary (version 62,
September 2011). When the owner of an intervention could
not be found, we also searched Wikipedia, company Web
sites, and drug-related Web sites [27]. Four independent re-
searchers extracted the data and discrepancies were dis-
cussed to reach consensus.
2.2. Statistical analysis
We present descriptive statistics (medians and interquar-
tile range for continuous variables, proportions for discrete
variables) on the characteristics of head-to-head comparison
trials. We further evaluated all these characteristics in rela-
tionship to the type of funding to assess whether industry-
sponsored trials were different than nonprofit funded and
those where no funding was listed. Descriptive data on trial
characteristics are also presented separately for the 12 com-
panies sponsoring the largest number of eligible studies.
We also estimated the number of RCTs with more than
one sponsor and examined whether any trials were funded
by companies which were not the owners of the products
under evaluation. After the methodology by Lathyris
et al. [9], we described the network and degree of cospon-
sorship by companies through a matrix that included the 12
companies with the most prolific trial agenda. Each com-
pany was tabulated against each of the others to visualize
the number of the RCTs that have been cosponsored. In
the network, each company is shown by a node whose
diameter is proportional to the number of sponsored trials.
Lines connecting two nodes represent cosponsorship be-
tween industries; the thickness of each link is proportional
to the number of cosponsored trials. Around each node,
there are loops whose thickness is proportional to the num-
ber of trials that were funded only by the company repre-
sented by the respective node.
Finally, we evaluated in exploratory analyses whether
industry funding, larger sample size, and design (noninfer-
iority/equivalence rather than superiority) were associated
with ‘‘favorable’’ results in univariate and multivariate lo-
gistic regressions. The variables mentioned previously were
forced to entry. We also tested whether any of the other re-
corded variables (affiliation, registration, impact factor,
country, intervention type, conflict of interest) was signifi-
cantly associated with favorable results in the final model,
but none remained statistically significant when funding
source and study design were adjusted for in the model.
Statistical significance was defined as a two-sided P-
value !0.05, and all analyses were carried out using Stata
11.1 (Stata Corp., College Station, TX, USA, 2011).3. Results
3.1. Characteristics of included trials
Fig. 1 shows the flow diagram of trial selection process.
Among 6,526 potentially eligible reports of RCTs, 498
Fig. 1. Flow diagram of the search. Study selection was made
applying the criteria below reported in the same order in which they
are shown in the Figure. RCT, randomized controlled trial.
Table 1. Characteristics of included trials
Variables
Overall sample
(n [ 319)
Trial sample, median (IQR) 300 (446)
Location of the RCTs, n (%)
United States 62 (19.4)
Western Europe 73 (22.9)
Asia 68 (21.3)
Internationala 93 (29.2)
Others 23 (7.2)
Context under evaluation, n (%)
Cardiovascular disorders 57 (17.9)
Cancer 44 (13.8)
Infectious diseases 40 (12.5)
Anesthesiology 20 (6.3)
Diabetes mellitus 18 (5.6)
Others 140 (43.9)
Type of intervention, n (%)
Drugs 288 (90.3)
Biologics 31 (9.7)
Compared interventions (ATC class), n (%)
Anti-infectives for systemic use 35 (11.0)
Antineoplastic and immunomodulating agents 61 (19.1)
Nervous system 52 (16.3)
Alimentary tract and metabolism 47 (14.7)
Cardiovascular system 38 (11.9)
Blood and blood forming organs 27 (8.5)
Genitourinary system and sex hormones 16 (5.0)
Antiparasitic products 11 (3.5)
Dermatologicals 10 (3.1)
Musculoskeletal system 10 (3.1)
Respiratory system 7 (2.2)
Sensory organs 2 (0.6)
Systemic hormonal preparations (excluding
sex hormones)
1 (0.3)
Various 2 (0.6)
Trials with common backbone treatment, n (%) 85 (26.6)
Registered trials, n (%) 222 (69.6)
Trial design, n (%)b
Superiority 233 (73.0)
Noninferiority 73 (22.9)
Equivalence 12 (3.8)
Trials with favorable results, n (%) 235 (73.7)
Journal impact factor, median (IQR) 3.4 (4.1)
Number of citations, median (IQR) 6 (12)
Type of funding source, n (%)
Pharmaceutical companies 182 (57.0)
Nonprofit institutions 87 (27.3)
Not reported 50 (15.7)
Trials sponsored by O1 company, n (%) 23 (7.2)
Authors’ affiliation, n (%)
Academic only 117 (36.7)
Both academic and nonprofit 64 (20.0)
Nonprofit only 14 (4.4)
Industry (at least one author) 124 (38.9)
Authors declaring a conflict of interest, n (%)c 185 (58.0)
Abbreviations: IQR, interquartile range; RCT, randomized
controlled trial; ATC, Anatomical Therapeutic Chemical classification
system.
a Trials conducted in countries from different continents.
b N 5 318 (one trial with unspecified design was excluded from
the comparison).
c Presence of a potential conflict of interest with the sponsors or
owners, as declared in the article (see text for details).
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(7.6%). After the exclusion of the RCTs with!100 partic-
ipants, 319 head-to-head RCTs were included in the
analysis.
Table 1 lists the main characteristics of the trials (refer-
ences appear in the Appendix). The median sample size
was 300, and only 46 trials exceeded 1,000 participants
(6 trials exceeded 10,000 participants). Almost 30% of
the 319 trials enrolled participants from multiple countries;
22.9% of the trials were carried out in Western Europe only,
21.3% in Asia, and 19.4% in the United States. Most trials
(90.3%) tested the efficacy and/or safety of two or more
drugs; biologics were compared in 9.8% of the sample,
and no trial compared medical devices. A wide variety of
diseases and types of interventions were evaluated. In 85
trials (26.6%), a common backbone treatment was adminis-
tered to all patients enrolled. Most trials (69.6%) posted the
protocol into a registry (ClinicalTrials.gov in 95.4% of the
registered studies). Excluding backbone treatments, 249 tri-
als (78.1%) entailed an antagonistic comparison of active
interventions owned by different companies. Almost
three-quarters (73%) had a superiority design, and a similar
815M.E. Flacco et al. / Journal of Clinical Epidemiology 68 (2015) 811e820proportion (73.7%) reported ‘‘favorable’’ findings. The pro-
portion of ‘‘favorable’’ findings was 68.2% (159 of 233) for
superiority designs and 88.2% (75 of 85) for noninferiority/
equivalence designs.
3.2. Funding source
As reported in Table 1, more than half of the trials had
industry sponsoring (57%) and these trials accounted for
238,386 of the 289,718 randomized participants (82.3%).
Trials supported by not-for-profit institutions were 27.3%
(14.6% of the randomized participants); 15.7% RCTs
(3.1% of the randomized participants) did not report a
source of funding.
Only 23 of 182 industry trials (12.6%) were funded by
more than one company (Table S1/Appendix at www.
jclinepi.com), and only nine (2.8%) were also supported
by nonprofit institutions. The great imbalance between co-
sponsored trials and trials supported by a single company is
visualized in Fig. 2, which displays the network of cospon-
sorship for the 12 most prolific companies.
As shown, the thickness of the autoloops (which repre-
sent trials sponsored by one company) is very large in pro-
portion to the sparse links between pairs of different
companies. Six of the 12 companies had not cosponsored
any trial with any of the other major companies. For
descriptive purposes, we have reported the main character-
istics of the 101 trials sponsored by these 12 companies
(Table S2/Appendix at www.jclinepi.com).
Most of the 23 cosponsored trials (n 5 18) were
funded by companies, which were also the owners of
the products under antagonistic evaluation (Tables S1
and S3/Appendix at www.jclinepi.com): in 11 of the
18, a product was co-owned by the two sponsors; in 8
of the 18, one of the sponsors owned both interventions
(the standard of care and the new drug); and in 3 of
the 18, one of the sponsors, in addition to the ownership
of an active comparator, commercialized a common
backbone treatment given to all arms. Only in 3 of 18 tri-
als [PubMed identification codes (PMID)d20890207,
21397567, 21729834], two different companies owned
two different active treatments and supported the com-
parison between them. In the remaining five trials
(PMID 21149659, 21388938, 21434995, 21652683, and
21775930), one of the sponsors did not own any of the
compared drugs, but it commercialized the common
backbone treatment given to all arms. Of the 23 cospon-
sored trial reports, three were secondary analyses of tri-
als whose primary results had been published previously,
and in none of the three, the primary results publication
had been sponsored only by a single company.
Based on authors’ affiliation, 38.9% of the trials had at
least one author affiliated to industry; 56.7% had been
authored by researchers with an academic/nonprofit affil-
iation (Table 1). Overall, there was some conflict of inter-
est between the authors and the industry in 58.0% of the
trials.3.3. Trial characteristics by funding source
As shown in Table 2, industry vs. other trials were
significantly more likely to involve international research
groups, enrolled a higher number of participants, were
more likely to be registered, use noninferiority designs,
have ‘‘favorable’’ results, be published on high-impact sci-
entific journals, and were also more cited. The same pattern
was seen for industry-sponsored trials vs. the group of
nonprofit trials [although the difference was not nominally
significant for journal impact factor (P 5 0.2), number of
citations (P 5 0.7), presence of an antagonistic comparison
(P 5 0.13)] and vs. trials without listed funding. Of the 50
trials without listed funders, only one was done in multiple
countries, only one was registered, and the sample size
tended to be small, while their impact was generally very
limited. Seven of the nine trials cosponsored by both profit
and nonprofit institutions showed positive findings (77.8%),
in line with the rest of industry trials (P 5 0.7).
3.4. Association of industry funding, sample size, and
design with ‘‘positive’’ results
In univariate analyses, industry funding, noninferiority/
equivalence design, and larger sample size were associated
with higher proportion of ‘‘favorable’’ results (Table 3). In
multivariate analyses considering all three variables,
although the prevalence of ‘‘favorable’’ results was signifi-
cantly higher among industry trials than other trials
[adjusted odds ratio (OR) 2.8; 95% confidence interval
(CI): 1.6, 4.7; P ! 0.001] and with noninferiority/equiva-
lence design (adjusted OR 3.2; 95% CI: 1.5, 6.6;
P 5 0.002) compared with superiority design, it did not in-
crease with larger sample size (Table 3). None of the other
recorded variables was significantly associated with favor-
able findings at multivariate analysis. Almost all RCTs with
a noninferiority/equivalence design funded by the industry
had ‘‘favorable’’ findings (55 of 57, 96.5%).4. Discussion
Our empirical evaluation assessed 319 recent head-to-
head randomized trials across a wide spectrum of treat-
ments and conditions. Most head-to-head comparative
evidence is procured by industry-sponsored trials. Typi-
cally, only one industry sponsor is involved, apparently
with an objective to obtain evidence on its product that
could be used for promotion. Noteworthy, the vast majority
of industry trials were funded exclusively by companies, as
only 2.8% were cosponsored by nonprofit institutions.
Industry-sponsored trials tend to be larger, they are more
frequently registered, and they tend to have higher citation
impact and ‘‘favorable’’results for the experimental treatment.
Industry-sponsored trials also use noninferiority/equivalence
designs more frequently than other trials. Industry funding
andnoninferiority/equivalencedesigns are strongly associated
Fig. 2. Network of cosponsorship for the 12 most prolific companies. Each company is shown by a node whose diameter is proportional to the num-
ber of trials sponsored. Lines represent cosponsorship between companies, with thickness proportional to the number of trials cosponsored. Dashed
lines refer to comparison with only one cosponsored trial. The thickness of the autoloops is proportional to the number of trials where the respective
company is the unique sponsor. Red circles into each node represent the proportion of trials sponsored (or cosponsored) by each company that
showed favorable results to the specific company (corresponding percentages are listed next to each node). BMS, Bristol-Myers Squibb.
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trials get desirable ‘‘favorable’’ results.
It has been speculated whether industry tends to avoid
head-to-head comparisons to avoid jeopardizing its marketshare by unfavorable results [9,28,29]. However, we docu-
mented that among the head-to-head RCTs that are eventu-
ally performed, the industry still has the lion’s share of this
research agenda, which can be highly influential for
Table 2. Characteristics of the included trials according to the funding source (n 5 319)
Variables
For-profit companies
(n [ 182; 57.0%)
Nonprofit institutions only
(n [ 87; 27.3%)
Funding source not reported
(n [ 50; 15.7%) P-valuea
Trial sample, median (IQR) 419 (642) 212 (260) 137 (110) !0.001
Location of the RCTs, % !0.001
United States 25.8 14.9 4.0
Western Europe 19.2 32.2 20.0
Asia 8.2 26.4 60.0
Internationalb 43.4 14.9 2.0
Others 3.3 11.5 14.0
Context under evaluation, % !0.001
Infectious diseases 10.4 20.7 6.0
Cardiovascular disorders 21.4 17.2 6.0
Cancer 13.7 17.2 8.0
Anesthesiology 4.4 3.5 18.0
Diabetes mellitus 8.9 2.3 0.0
Others 41.2 39.1 62.0
Type of intervention, n (%) 0.8
Drugs 92.0 88.5 90.7
Biologics 8.0 11.5 9.3
Compared interventions (ATC class), n (%) 0.001
Anti-infectives for systemic use 9.9 14.9 8.0
Antineoplastic and immunomodulating agents 23.1 18.4 6.0
Nervous system 12.1 16.1 32.0
Alimentary tract and metabolism 13.2 17.2 16.0
Cardiovascular system 13.7 12.6 4.0
Blood and blood forming organs 11.5 4.6 4.0
Genitourinary system and sex hormones 3.3 3.5 14.0
Antiparasitic products 1.6 8.0 2.0
Dermatologicals 3.8 0.0 6.0
Musculoskeletal system 3.3 1.2 6.0
Respiratory system 3.3 1.2 0.0
Sensory organs 0.5 1.2 0.0
Systemic hormonal preparations (excluding
sex hormones)
0.0 0.0 2.0
Various 0.5 1.1 0.0
Trials with common backbone treatment, % 25.8 31.0 22.0 0.5
Registered trials, % 86.3 73.6 2.0 !0.001
Trial design, %c 0.012
Superiority 68.7 75.9 85.7
Noninferiority 29.1 18.4 8.2
Equivalence 2.2 5.7 6.1
Trials with favorable results, % 83.3 58.6 70.0 !0.001
Journal impact factor, median (IQR) 4.0 (4.7) 3.8 (4.0) 1.3 (1.5) !0.001
Number of citations, median (IQR) 8 (23) 5 (8) 2.5 (4) !0.001
Authors’ affiliation, % !0.001
Academic only 14.8 59.8 76.0
Both academic and nonprofit 15.4 34.5 12.0
Nonprofit only 3.3 3.4 10.0
Industry (at least one author) 66.5 2.3 2.0
Authors declaring a conflict of interest, % 91.8 16.1 8.0 !0.001
Abbreviations: IQR, interquartile range; RCT, randomized controlled trial; ATC, Anatomical Therapeutic Chemical classification system.
a Chi-squared test for categorical variables; one-way ANOVA for continuous ones.
b Trials conducted in countries from different continents.
c N 5 318 (one trial with unspecified design was excluded from the comparison).
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ponderance of industry sponsorship in head-to-head trials
has also been demonstrated in previous smaller evaluations
of trials in specific areas of cardiovascular and psychiatric
disorders [5e8] and H1N1 influenza vaccines [27,30].
We found that more than three-quarters of the head-to-
head trials compared products owned by differentcompanies, with no significant difference between industry
and nonindustry-funded trials. However, we observed that
cosponsorship of antagonistic trials was infrequent.
Twenty-three RCTs were supported by two (or more)
different companies; however, only in three of these (0.9%
of the total sample) two sponsors, each owning an active
treatment, were truly compared against each other. In the
Table 3. Relationship between favorable results, type of sponsorship, trial design and sample: percentage, odds ratio (OR) and 95% confidence
interval (CI)
Variables %a
Univariate Multivariate
OR (95% CI)a P-value OR (95% CI)a P-value
Type of sponsorship:
Not-for-profit institutions (reference category) 62.8 1 d 1 d
Pharmaceutical companies 82.3 2.8 (1.7, 4.7) !0.001 2.8 (1.6, 4.7) !0.001
Trial design:
Superiority (reference category) 68.5 1 d 1 d
Noninferiority/equivalence 88.2 3.4 (1.7, 7.0) 0.001 3.2 (1.5, 6.6) 0.002
Sample size
100e200 participants (reference category) 69.6 1 d 1 d
201e500 75.0 1.3 (0.7, 2.3) 0.4 0.9 (0.5, 1.8) 0.9
More than 500 77.8 1.6 (0.8, 2.9) 0.18 0.9 (0.5, 1.9) 0.8
a Proportion or odds ratio of ‘‘favorable’’ results (see text for details).
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ship of the same intervention(s), or one of the sponsors was
the owner of the common backbone treatment given to all pa-
tients, or owned both the interventionsdthe standard of care
and the new drug. In this way, sponsoring companies have to
gain from the trial regardless of the outcome, unless a com-
pany owns and compares a new drug against an older one,
which is about to go off patent. In this peculiar case, the com-
pany would not gain if the old drug proves to be as good, or
even better, than the new one. Overall, each company tended
to support almost exclusively trials focused on its own prod-
ucts, trying to prove its new agent superior or noninferior to
some established comparator.
As for randomized trials in general [31], the profile and
characteristics of head-to-head trials appear to be influenced
by their sponsorship. Compared with nonindustry RCTs, in-
dustry trials had higher rates of registration, larger sample
size, were published on journals with higher impact factors,
and were more cited. All these findings tend to suggest that
industry-sponsored head-to-head RCTs are outperforming
other head-to-head trials. This is not surprising because sup-
porting companies see these trials as an investment that is
important for their marketing efforts, and thus, they want to
optimize the compliance with requested policies (such as
registration) and the impact of this research. Moreover, com-
panies are expected to meet standard quality criteria during
the planning and conducting of clinical trials and are subject
to intense scrutiny by regulatory agencies [32].
Also, as previously hypothesized [7,33,34], we found
that industry trials were more likely than other trials to
adopt a noninferiority/equivalence design. There are two
potential motivations for using noninferiority designs. First,
often there can be advantages in terms of sample size (and,
in turn, costs) [7,21]. Moreover, proving noninferiority of a
new product may be sometimes less risky than aiming to
establish its superiority because a finding of noninferiority
will require less of a treatment effect yet still may be
enough to support product approval [33,35]. Along with
this increasing trend, however, growing concerns occur:
some argue that noninferiority RCTs mainly benefitcompanies, as they allow drugs without additional clinical
efficacy to enter the market [20,36,37]. However, admit-
tedly, these drugs may still be useful if they are safer and
less expensive [38e40]. We found that published
industry-sponsored trials with noninferiority/equivalence
designs were practically almost always successful to get a
favorable, ‘‘positive’’ result, that is, claim (at least) nonin-
feriority. Unfortunately, no information is available to eval-
uate whether such a high success rate occurs among all
trials including those that remain unpublished or whether
pharmaceutical companies selectively fund trials on drugs
that they consider to be superior to the competition. In
any case, by focusing on noninferiority, companies shift
the traditional concept of equipoise where typically only
about half of the trials manage to show superiority of the
new treatment against a standard comparator [41e45] and
select a design and inferential framework that is more likely
to give them favorable results [46].
Although we found an independent, significant relation-
ship between reporting positive findings and being spon-
sored by industry or having a noninferiority/equivalence
design, trial results were not related to sample size. An as-
sociation between industry sponsorship and positive find-
ings has been documented by several surveys of clinical
trials [5e8,19,26,47e49]. Sample size was previously
found to be associated with favorable findings in few
empirical surveys [6,50], only one of which focused on
head-to-head trials [6] and the association was seen for
favorable trial conclusions rather than favorable trial results
per se. Our analysis might also be partially affected by the
exclusion of smaller RCTs.
Previous literature has showed an association between the
presence of author’s conflict of interest and favorable find-
ings in randomized trials [51e53]. Because of the strong cor-
relation between funding source and conflict of interest
(Spearman rho 0.77), the variable ‘‘conflict of interest’’
was not significant in multivariate analysis in our survey.
However, if funding source was removed from the model,
the presence of a conflict of interest would have been signif-
icantly associated with favorable findings (not shown).
819M.E. Flacco et al. / Journal of Clinical Epidemiology 68 (2015) 811e820Some limitations should be acknowledged. First, it is
possible that we failed to identify funding sources and
financial ties in some of the included trials. We classified
trials as industry funded or not based on each article’s
disclosure of its funding source(s), and only if no funding
source was listed in the article, we checked the correspond-
ing trial registration record, if available. Krimsky et al.
[54,55] showed, however, that there is a lack of disclosure
of industry research support and personal financial ties
across a wide variety of journals. Thus, we may have under-
estimated the number of industry-sponsored trials and per-
sonal financial ties of investigators. Second, we tried to
ascertain all potential relationships between companies,
but sometimes financial arrangements remain undetected
in internet searches, especially those between small com-
panies with larger ones [9]. Third, because industry-
funded trials and drug trials are more likely to have large
samples [6,56], the exclusion from our analyses of RCTs
with !100 patients may have led to underrepresentation
of nonindustry-funded trials and device trials in our sample.
Finally and most importantly, we only examined a
(large) sample of RCTs published in 2011, and thus, we
cannot map whether any changes in these patterns of
head-to-head trials might have occurred over the years.
However, our survey offers evidence on the profile of trials
that were published in the recent literature.
In conclusion, there is strong dominance of the industry
in the influential agenda of head-to-head comparisons, con-
firming the unbalance between profit and nonprofit spon-
sored sources of data of current literature. We observed a
high prevalence of results that were favorable for the spon-
soring companies, which may have several explanations
including: (1) industry trials may be conducted more rigor-
ously than nonprofit trials and are thus genuinely more suc-
cessful; (2) pharmaceutical companies may selectively fund
trials that are more likely to yield favorable results
(possibly due to the many preliminary phase 1 and phase
2 studies that are conducted before embarking on phase
3); (3) industry trials choose suboptimal outcomes, compar-
ators, and other design features that can secure a favorable
result; or (4) trials with unfavorable findings may be less
likely to be published by companies. It is currently impos-
sible to determine the relative weight of each of the above,
but given the importance of head-to-head comparisons in
informing guideline recommendations and practice, consid-
eration should be given to allowing the conduct of more
large trials of comparative effectiveness and safety under
the control of nonprofit entities [57]. The design of such tri-
als should be such as to inform important questions rather
than pre-emptively ensure that results would be favorable
for a tested intervention.
Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jclinepi.2014.12.016.References
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